{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:23:18Z","timestamp":1784305398152,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.esmoop.2024.102386","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T19:18:35Z","timestamp":1710875915000},"page":"102386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-2414","authenticated-orcid":false,"given":"T.","family":"Al-Toubah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-7222","authenticated-orcid":false,"given":"B.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Valone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8405-218X","authenticated-orcid":false,"given":"J.","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2024.102386_bib1","first-page":"3368","article-title":"Distinct expression patterns of VEGFR 1-3 in gastroenteropancreatic neuroendocrine neoplasms: supporting clinical relevance, but not a prognostic factor","volume":"9","author":"B\u00f6sch","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102386_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/ijc.25441","article-title":"VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis","volume":"128","author":"Silva","year":"2011","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102386_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102386_bib4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102386_bib5","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102386_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/ERC-16-0008","article-title":"A\u00a0phase II study of axitinib in advanced neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.102386_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/JCO.2017.35.4_suppl.228","article-title":"Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET)","volume":"35","author":"Chan","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2024.102386_bib8","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2019.37.15_suppl.4005","article-title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202)","volume":"37","author":"Bergsland","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2024.102386_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.2021.39.3_suppl.360","article-title":"A\u00a0phase II\/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107)","volume":"39","author":"Garcia-Carbonero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2024.102386_bib10","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102386_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"Ribatti","year":"2022","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102386_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbrc.2005.06.065","article-title":"Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways","volume":"334","author":"Laxmanan","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.esmoop.2024.102386_bib13","doi-asserted-by":"crossref","first-page":"V142","DOI":"10.1093\/annonc\/mdx368","article-title":"Pembrolizumab for patients with PD-L1\u2013positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","volume":"28","author":"Mehnert","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.102386_bib14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41416-020-0775-0","article-title":"Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials","volume":"122","author":"Vijayvergia","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.102386_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2022.03.029","article-title":"Avelumab in unresectable\/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): combined results from NET-001 and NET-002 trials","volume":"169","author":"Chan","year":"2022","journal-title":"Eur J Cancer"},{"issue":"suppl 8","key":"10.1016\/j.esmoop.2024.102386_bib17","doi-asserted-by":"crossref","first-page":"VIII467","DOI":"10.1093\/annonc\/mdy293.001","volume":"29","author":"Yao","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.102386_bib27","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102386_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2024.102386_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102386_bib20","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102386_bib21","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"issue":"26","key":"10.1016\/j.esmoop.2024.102386_bib22","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102386_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102386_bib24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3892\/etm.2021.10613","article-title":"The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5","volume":"22","author":"Popa","year":"2021","journal-title":"Exp Ther Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102386_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102386_bib26","article-title":"Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors","volume":"10","author":"Mandriani","year":"2022","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924001546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924001546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:30:22Z","timestamp":1714469422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924001546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2059702924001546"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102386","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102386"}}